01 marzo 2014

JACC. Impact of Smoking on Long-Term Outcomes in Patients With Atherosclerotic Vascular Disease Treated With Aspirin or Clopidogrel. Insights From the CAPRIE Trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events)

José L. Ferreiro, MD∗; Deepak L. Bhatt, MD, MPH‡; Masafumi Ueno, MD, PhD∗; Deborah Bauer, MS§; Dominick J. Angiolillo, MD, PhD∗

Objectives: The goal of this study was to investigate the differential efficacy of clopidogrel or aspirin monotherapy according to smoking status in patients with atherosclerotic vascular disease.

01 febrero 2014

JACC. Percutaneous Interventional Therapies for the Treatment of Patients With Severe Pulmonary Hypertension

Paul Bhamra-Ariza, MBBS, MD∗; Anne M. Keogh, MBBS, PhD∗; David W.M. Muller, MBBS, MD∗

Despite improvements in medical therapy, the overall prognosis of patients with severe pulmonary arterial hypertension remains poor. Heart-lung transplantation or bilateral lung transplantation is the final pathway for a minority. This paper describes both established and novel percutaneous interventional techniques that may palliate or bridge pulmonary hypertension patients to transplantation.

01 febrero 2014

JACC. Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. Insights From the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention)

Philippe Généreux, MD∗; Gregg W. Stone, MD∗; Robert A. Harrington, MD§; C. Michael Gibson, MD‖; Ph. Gabriel Steg, MD¶; Sorin J. Brener, MD†; Dominick J. Angiolillo, MD, PhD∗∗; Matthew J. Price, MD††; Jayne Prats, PhD‡‡; Laura LaSalle, MPH†; Tiepu Liu, MD, PhD††; Meredith Todd, BSc††; Simona Skerjanec, PharmD††; Christian W. Hamm, MD§§; Kenneth W. Mahaffey, MD§; Harvey D. White, DSc‖‖; Deepak L. Bhatt, MD, MPH¶¶

Objectives: This study sought to evaluate the clinical impact of intraprocedural stent thrombosis (IPST), a relatively new endpoint.

01 febrero 2014

JACC. Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. A PRODIGY Trial Substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)

Gianluca Campo, MD∗; Matteo Tebaldi, MD∗; Pascal Vranckx, MD, PhD‡; Simone Biscaglia, MD∗; Carlo Tumscitz, MD∗; Roberto Ferrari, MD, PhD∗; Marco Valgimigli, MD, PhD∗

Objectives: This study sought to investigate the clinical outcome of patients treated with percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) randomized to short (6 months) versus long (24 months) dual antiplatelet therapy (DAPT) regimen.

21 marzo 2014

EUROPEAN HEART JOURNAL. Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study

Maria D. Radu1,2,†, Lorenz Räber1,3,†, Bindu Kalesan4, Takashi Muramatsu1, Henning Kelbæk2, Jungho Heo1, Erik Jørgensen2, Steffen Helqvist2, Vasim Farooq1, Salvatore Brugaletta1, Hector M. Garcia-Garcia5, Peter Jüni4, Kari Saunamäki2, Stephan Windecker3 and Patrick W. Serruys1,*

Objectives: The purpose of this study was to assess the occurrence, predictors, and mechanisms of optical coherence tomography (OCT)-detected coronary evaginations following drug-eluting stent (DES) implantation.

21 marzo 2014

EUROPEAN HEART JOURNAL. PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design

Erik W. Holy1,2,3,4, Philipp Jakob1,2,3, Thomas Eickner5, Giovanni G. Camici2,3, Jürg H. Beer4, Alexander Akhmedov2,3, Katrin Sternberg5, Klaus-Peter Schmitz5, Thomas F. Lüscher1,2,3 and Felix C. Tanner1,2,3,*

Background: Impaired re-endothelialization and stent thrombosis are a safety concern associated with drug-eluting stents (DES). PI3K/p110α controls cellular wound healing pathways, thereby representing an emerging drug target to modulate vascular homoeostasis after injury.

01 marzo 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Transvascular closure of single and multiple muscular ventricular septal defects in neonates and infants < 20 kg

Peter Zartner MD, FESC1,*, Claus Christians MD1, Jan-Christian Stelter MD1, Viktor Hraška MD, PhD2 andMartin B.E. Schneider Prof. MD1

Purpose: While surgical closure of ventricular septal defects (VSD) is still the gold standard, we review our experience with the interventional closure of single and multiple muscular VSD in newborns and infants under 20 kg.

01 marzo 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. UK multicenter experience using the gore septal occluder (GSOTM) for atrial septal defect closure in children and adults

Ben Smith MD1, John Thomson MD2, David Crossland MD3, Mark S. Spence MD4 andGareth J. Morgan MD5,*

Background: Percutaneous closure of atrial defects (ASD) has evolved as the treatment of choice for the majority of defects and patent oval foramens. The Gore Septal Occluder (GSO) is an innovative device consisting mostly of a folded thin GoreTex tube for use in the closure of septal defects.

01 marzo 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Incidence and implications of idiopathic thrombocytopenia following transcatheter aortic valve replacement with the Edwards Sapien© valves: A single center experience

James M. McCabe MD1,*, Pei-Hsiu Huang MD2, Lauren A. Riedl PAC2, Srikanth R. Devireddy BA2, Jennifer Grondell RN2, Annie C. Connors RN2, Michael J. Davidson MD3, Andrew C. Eisenhauer MD2 andFrederick G. P. Welt MD MS2

Objectives: To determine the incidence and etiology of thrombocytopenia following transcatheter Aortic valve replacement (TAVR).

01 marzo 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Significance of the learning curve in left atrial appendage occlusion with two different devices

Ignacio Cruz-Gonzalez MD, PhD1,*, Angel Perez-Rivera MD1, Rosana Lopez-Jimenez MD1, Javier Rodriguez-Collado MD1, Javier Martín-Moreiras MD1, Manuel Cascon MD, PhD1, Antonio Arribas MD, PhD1, Jose Carlos Gomez MD, PhD2, Andrew O. Maree MD, PhD3 andCandido Martin-Luengo MD, PhD1

Objective: To evaluate the impact of learning on outcome with use of two different left atrial appendage (LAA) occlusion devices.

01 marzo 2014

JACC: CARDIOVASCULAR INTERVENTIONS. A Great Start, But the Promise of Biodegradable Stents Remains to Be Proven

Barry T. Katzen, MD

In this issue of JACC: Cardiovascular Interventions, Werner et al. 1 present their experience with the use of a biodegradable balloon expandable stent for use in the superficial femoral artery (SFA). This stent, which is commercially available outside the United States, is composed of poly-L-lactic acid (PLLA) and undergoes degradation in the human body through a process of hydrolysis over a long period of time. In this particular device, structural integrity is maintained for 6 months, following which, degradation begins and can last up to 3 years, at which point no more material is detectable.

01 marzo 2014

JACC: CARDIOVASCULAR INTERVENTIONS. One Versus Two Stents. The Cause or the Effect?

Antonio Colombo, MD; Alaide Chieffo, MD

It is now almost a decade that we have been discussing optimal treatment of bifurcation lesions, and invariably we come to the unanswered question: 1 or 2 stents?

01 marzo 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Effect of the Endothelial Shear Stress Patterns on Neointimal Proliferation Following Drug-Eluting Bioresorbable Vascular Scaffold Implantation. An Optical Coherence Tomography Study

Christos V. Bourantas, MD, PhD∗; Michail I. Papafaklis, MD, PhD†; Anna Kotsia, MD‡; Vasim Farooq, MB, ChB∗; Takashi Muramatsu, MD, PhD∗; Josep Gomez-Lara, MD, PhD∗; Yao-Jun Zhang, MD, PhD∗; Javaid Iqbal, PhD∗; Fanis G. Kalatzis, MD, PhD§; Katerina K. Naka, MD, PhD‡; Dimitrios I. Fotiadis, PhD§; Cecile Dorange, MSc‖; Jin Wang, PhD¶; Richard Rapoza, PhD¶; Hector M. Garcia-Garcia, MD, PhD∗; Yoshinobu Onuma, MD∗; Lampros K. Michalis, MD‡; Patrick W. Serruys, MD, PhD∗

Objectives: This study sought to investigate the effect of endothelial shear stress (ESS) on neointimal formation following an Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) implantation.

01 marzo 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Provisional Stenting of Coronary Bifurcations. Insights Into Final Kissing Balloon Post-Dilation and Stent Design by Computational Modeling

Peter Mortier, PhD∗; Yutaka Hikichi, MD‡; Nicolas Foin, PhD§; Gianluca De Santis, PhD∗; Patrick Segers, PhD†; Benedict Verhegghe, PhD∗; Matthieu De Beule, PhD∗

Objectives: This study sought to better understand and optimize provisional main vessel stenting with final kissing balloon dilation (FKBD).

01 marzo 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Optical Coherence Tomography Appearances in Healed Coronary Artery Aneurysms After Stent Implantation

Girish N. Viswanathan, MBBS, MD∗; Saqib Chowdhary, MBBS, PhD†; Richard A. Anderson, BSc, MBBS, MD‡

We earlier reported late stent malapposition and marked coronary artery aneurysm (CAN) formation at the site of implantation of 2 bare-metal stents (BMS), Multilink Vision (Abbott Laboratories, Abbott Park, Illinois) and Liberte (Boston Scientific Corporation, Natick, Massachusetts), to the proximal left anterior descending artery (LAD) and right coronary artery (RCA), respectively, in a woman treated for stable angina in 2006. The patient also had a Xience drug-eluting stent (DES) (Abbott Laboratories) to her mid RCA with less marked CAN on angiography in 2007 1. Diagnostic coronary angiography and optical coherence tomography (OCT) assessment was performed in 2012, although she remained free of symptoms or hospitalizations. Five years later, coronary angiography showed partial angiographic resolution of the CAN in the 2 BMS segments, with continued aneurysm formation at the Xience DES implantation site